Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
What the Clinical Evidence Shows Phase 2 Trial Results The primary Phase 2 data was published in the New England Journal of Medicine in 2023
Further solidifying 2025 as the year of updates to clinical frameworks, the European Association for the Study of Obesity released a new pharmacotherapy framework [3]
10.1126/sciadv.abf1948 18 FortinJ.-P.SchroederJ
The ongoing 240-week follow-up in ESSENCE will be critical for determining whether semaglutide-driven histologic improvements translate into reductions in clinically meaningful events
Long-term studies are also needed to assess whether GLP-1RAs can prevent progression from PsO to PsA, improve musculoskeletal outcomes, and reduce systemic comorbidities such as cardiovascular disease
B12 is an essential vitamin that is necessary for good health
